dmf dimethyl formamide dmso dimethylsulfoxide edta ethylene diamine tetraacetic acid peg polyethylene glycol ted buffer tris edta dtt thf tetrahydrofuran tris hcl tris hydroxymethyl aminomethyl hydrochloride the term u201c subject u201d as used herein refers to an animal preferably a mammal most preferably a human who has been the object of treatment observation or experiment the term u201c therapeutically effective amount u201d as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system animal or human that is being sought by a researcher veterinarian medical doctor or other clinician which includes alleviation of the symptoms of the disease or disorder being treated as used herein the term u201c composition u201d is intended to encompass a product comprising the specified ingredients in the specified amounts as well as any product which results directly or indirectly from combinations of the specified ingredients in the specified amounts the compounds of the present invention may be prepared from known compounds or compounds prepared by known methods for example the compounds of formula i of the present invention wherein two adjacent r groups i e r 4 and r 5 r 6 and r 7 or r 7 and r 1 are taken together to form a six membered heterocyclyl ring may be prepared from the starting materials labeled s1 through s9 compounds of formula s4 s5 and s6 may be prepared from known compounds by known methods for example compounds s4 and s6 may be prepared by known methods from 7 amino 4h benzo 1 4 oxazine 3 one and 6 amino 4h benzo 1 4 thiazin 3 one respectively the compound of formula s5 may.